STAGE III LUNG CANCER AJCC V8

This early-phase study is testing a personalized vaccine made from each patient's unique tumor mutations. The goal is to see if it is safe and can help the immune system fight advanced breast cancer, melanoma, and non-small cell lung cancer. About 25 adults whose cancers have spr…

This study tests whether adding an experimental drug called TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can better shrink tumors and extend life in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, maki…

This study tests whether giving two immunotherapy drugs (cemiplimab and fianlimab) before surgery can kill more tumor cells in people with stage IB to IIIB non-small cell lung cancer. About 60 adults will receive the drug combination before their tumor is removed. The goal is to …

This study tests whether adding a precise, high-dose radiation treatment (SBRT) to the tumor before standard chemoradiation and immunotherapy can help people with locally advanced lung cancer live longer. About 474 adults whose lung cancer has spread to nearby lymph nodes but can…

This study tests whether adding diclofenac, a common anti-inflammatory painkiller, can help control tumor growth in people with advanced non-small cell lung cancer whose disease is starting to worsen while on immunotherapy alone. About 20 adults with stage III or IV lung cancer w…

This study tests a personalized vaccine made from a patient's own tumor proteins, combined with the immunotherapy drug pembrolizumab, for people with advanced solid tumors. The goal is to see if this combination is safe and helps the immune system fight cancer more effectively. A…

This study tests a combination of two drugs, sotorasib and trastuzumab deruxtecan, in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation. The goal is to see if the combination is safe and can shrink tumors. About 37 adults who have already trie…

This early-stage trial tests whether combining two drugs, carfilzomib and sotorasib, is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change called KRAS G12C. About 15 adults who have already tried a KRAS-targeting drug will re…

This study tests a combination of two targeted drugs (defactinib and avutometinib) plus an immunotherapy (nivolumab) in 50 people with advanced LKB1-mutant lung adenocarcinoma that has stopped responding to standard anti-PD1 treatment. The goal is to see if this triple therapy ca…

This study tests a new drug combination (GT103 plus pembrolizumab) in people with advanced or spreading non-small cell lung cancer that has a specific gene change called STK11. The goal is to see if the combo can shrink tumors or slow the cancer better than current options. About…

This study is for people with stage III non-small cell lung cancer whose disease has gotten worse after standard chemoradiation and immunotherapy. It tests whether adding local treatments like surgery or radiation along with the immunotherapy drug durvalumab can help control the …

This study tests whether the drug canakinumab can prevent lung cancer in 50 people who have suspicious lung nodules that haven't gone away. Participants receive the drug and are monitored for nodule shrinkage, cancer development, and side effects. The goal is to see if this appro…

This study tests whether a home-based breathing exercise program can reduce shortness of breath, fatigue, and improve quality of life for people who have had surgery for early-stage lung cancer. About 100 survivors will be asked to do breathing exercises regularly for several wee…

This study looks at whether getting immunotherapy in the morning or afternoon changes how well it fights advanced or metastatic solid tumors. Researchers believe the body's internal clock (circadian rhythm) might affect immune response. About 160 adults with certain cancers like …

This study tests a method called adaptive radiation planning for people with stage II to IV non-small cell lung cancer. Normally, radiation plans stay the same throughout treatment, but tumors can shrink, causing radiation to hit healthy tissue. By updating the plan at set times,…

This study tests whether a yoga program designed for both patients and their family caregivers can improve physical function, fatigue, sleep, and quality of life. It includes 400 people with lung or esophageal cancer who are getting radiation therapy, plus their caregivers. Parti…

This study looks at how chemoradiation for locally advanced lung cancer affects the heart. Researchers will track 100 patients to see if tailoring treatment based on individual risk can reduce heart damage. The goal is to learn more about heart risks and improve safety without ch…

This study looks at how immune cells called T cells change in people with advanced melanoma, lung, or other cancers during anti-PD-1 therapy. Researchers will measure specific markers in blood samples to see if they can predict treatment response or resistance. The goal is to und…

This study looks at two standard surgical techniques for removing early-stage lung cancer: tying off the vein first versus the artery first. The goal is to see which method better reduces the amount of tumor DNA that gets into the bloodstream during surgery. About 100 adults with…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung, or genitour…

This study is testing whether a special communication tool helps doctors and lung cancer patients make treatment decisions together more effectively. The tool guides conversations about treatment options, benefits, and risks while considering each patient's personal situation and…